Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601432 | 0.81 | S1PR1 (0.57) | S1PR1HTTRAB9ANPC1LMNA | |
| SCHEMBL27778831 | 0.77 | ABCB1 (0.48) | HTTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL25728249 | 0.77 | TRPV1 (0.55) | S1PR1RAB9ANPC1LMNAHIF1A | |
| SCHEMBL13316478 | 0.75 | ABCB1 (0.46) | HTTRAB9ALMNAKMT2AALDH1A1 | |
| SCHEMBL3608887 | 0.74 | PTGS1 (0.53) | HTTLMNAALDH1A1SMN1; SMN2GABRA5 | |
| SCHEMBL13902147 | 0.69 | S1PR1 (1.00) | S1PR1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL1753170 | 0.69 | CACNA1F (0.48) | LMNAKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL13901830 | 0.69 | USP30 (0.64) | S1PR1RAB9ANPC1LMNAHIF1A | |
| Dinitrophenylene SCHEMBL27647742 | 0.69 | NPC1 (0.62) | RAB9ANPC1ALDH1A1 | |
| SCHEMBL13258190 | 0.67 | TRPV1 (0.81) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GLATTHAR RALF | 2010-06-03 | — | — | US | disclosed |
| EP-2132210-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | Novartis AG (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107418-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GRM1, GRM2, GRM3 | S1PR1 287/4885HTT 1403/4885RAB9A 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.